Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996273 | 0.96 | CTSL (0.57) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL15109512 | 0.96 | CTSL (0.57) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL19390721 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL133032 | 0.86 | SIRT2 (0.53) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL13434967 | 0.86 | SIRT2 (0.53) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL3902571 | 0.86 | SIRT2 (0.53) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL5218083 | 0.85 | SYK (0.57) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL8054994 | 0.85 | SIRT2 (0.55) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL5019087 | 0.84 | LMNA (0.61) | SMN1; SMN2NPC1RAB9ALMNACTSL | |
| SCHEMBL29632318 | 0.84 | SIRT2 (0.52) | SMN1; SMN2NPC1RAB9ALMNACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632972-B2 | Reacting an acid and an amine; apoptosis; carbamate, and N-phenethyl-2-phenylacetamide | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLIONIS (US) | 2009-12-15 | — | — | US | disclosed |
| US-20050197511-A1 | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells | NATIONAL SCIENCE FOUNDATION | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197511-A1 | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells | BAD, MCL1, CASP3 | SMN1; SMN2 2432/4885NPC1 4362/4885RAB9A 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.